UCSF Biobank for Hereditary Cancers and Tumor-Associated Mutations

Launched by UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · Mar 19, 2025

Keywords

ClinConnect Summary

The UCSF Biobank for Hereditary Cancers and Tumor-Associated Mutations is a research study aimed at collecting and storing samples from people with hereditary cancers. The goal is to create models of tumors that can help researchers understand these types of cancers better and work on developing new treatments. This study is not currently recruiting participants, but it will involve adults aged 18 and older who have solid tumors and either a personal or family history of cancer. Participants will need to provide consent and will be asked to undergo certain medical procedures, like biopsies or blood draws, as part of their routine care.

To be eligible, participants should be willing to sign a consent form and must be planning to have a biopsy, surgical procedure, or a blood draw. However, individuals with certain infectious diseases like HIV or Hepatitis B or C will not be eligible. By participating, individuals can contribute to important research that may improve our understanding of hereditary cancers and help in finding new ways to treat them in the future.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• For participants undergoing collection of tissue, ascites, and/or pleural effusions:
• • 1. Ability to understand and willingness to voluntarily sign a written informed consent document prior to any study-related assessments or procedures are conducted.
• • 2. Individuals 18 years of age or older on the day of signing informed consent.
• • 3. Individuals with solid tumor malignancy with germline or somatic cancer-associated mutations and/or Individuals with a family history or personal history of cancer.
• 4. Must be planning to undergo one of the following procedures as part of their routine care (or as a research procedure under a UCSF-sponsored IIT protocol):
• • 1. Surgical resection
• • 2. Biopsy (open, incisional, excisional, punch, core needle, and/or fine needle aspiration (FNA) are all permitted)
• • 3. Paracentesis
• • 4. Thoracentesis
• For participants undergoing blood banking:
• • 1. Ability to understand and willingness to voluntarily sign a written informed consent document prior to any study-related assessments or procedures are conducted.
• • 2. Individuals 18 years of age or older on the day of signing informed consent.
• • 3. Individuals with a family history or personal history of cancer.
• • 4. Must be planning to undergo a blood draw as part of their routine care (or as a research procedure under a University of California, San Francisco (UCSF) -sponsored investigator-initiated trial (IIT) protocol); or willing to undergo an additional blood draw outside of their routine care.
• Exclusion Criteria:
• • 1. Known history of HIV, Hepatitis B, or Hepatitis C (as documented in the medical record) or other infectious disease that in the judgment of the investigator could pose a risk to research personnel or mice, or negatively impact Patient derived xenografts (PDX) tumor engraftment.